Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Market exclusivity and the entry of adalimumab biosimilars in Europe : an overview of pricing and national policy measures

Autor: Moorkens, Evelien, Godman, Brian, Huys, Isabelle, Hoxha, Iris, Malaj, Admir, Keuerleber, Simon, Stockinger, Silvia, Mörtenhuber, Sarah, Dimitrova, Maria, Tachkov, Konstantin, Vončina, Luka, Palčevski, Vera Vlahović, Achniotou, Gnosia, Slabý, Juraj, Popelková, Leona, Kohoutová, Kateřina, Bartels, Dorthe, Laius, Ott, Martikainen, Jaana E., Selke, Gisbert W., Kourafalos, Vasileios, Magnússon, Einar, Einarsdóttir, Rannveig, Adams, Roisín, Joppi, Roberta, Allocati, Eleonora, Jakupi, Arianit, Viksna, Anita, Greičiūtė-Kuprijanov, Ieva, Vella Bonanno, Patricia, Suttorp, Vincent, Melien, Øyvind, Plisko, Robert, Mardare, Ileana, Meshkov, Dmitry, Novakovic, Tanja, Fürst, Jurij, Zara, Corinne, Marković-Peković, Vanda, Grubiša, Nataša, Befrits, Gustaf, Puckett, Robert, Vulto, Arnold G.

Background: From October 2018, adalimumab biosimilars could enter the European market. However, in some countries, such as Netherlands, high discounts reported for the originator product may have influenced biosimilar entry. Objectives: The aim of th

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______3549::3017ab381eabe94e09d7e7471b42582b
https://www.um.edu.mt/library/oar/handle/123456789/94432

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

The Expiry of Humira ^® Market Exclusivity and the Entry of Adalimumab Biosimilars in Europe: An Overview of Pricing and National Policy Measures.

Autor: Moorkens E; Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium., Godman B; Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, United Kingdom.; Division of Public Health Pharmacy and Management, School of Pharmacy, Faculty of Health Sciences, Sefako Makgatho Health Sciences University, Pretoria, South Africa.; Division of Clinical Pharmacology, Department of Laboratory Medicine, Karolinska Institutet, Karolinska University Hospital Huddinge, Stockholm, Sweden., Huys I; Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium., Hoxha I; Department of Pharmacy, University of Medicine Tirana, Tirana, Albania., Malaj A; Department of Pharmacy, University of Medicine Tirana, Tirana, Albania., Keuerleber S; Austrian Social Insurance, Vienna, Austria., Stockinger S; Austrian Social Insurance, Vienna, Austria., Mörtenhuber S; Austrian Social Insurance, Vienna, Austria., Dimitrova M; Faculty of Pharmacy, Medical University of Sofia, Sofia, Bulgaria., Tachkov K; Faculty of Pharmacy, Medical University of Sofia, Sofia, Bulgaria., Vončina L; Faculty of Health Studies, University of Rijeka, Rijeka, Croatia., Palčevski VV; Faculty of Health Studies, University of Rijeka, Rijeka, Croatia., Achniotou G; Health Insurance Organization (HIO), Nicosia, Cyprus., Slabý J; State Institute for Drug Control, Prague, Czechia., Popelková L; State Institute for Drug Control, Prague, Czechia., Kohoutová K; State Institute for Drug Control, Prague, Czechia., Bartels D; Amgros, Copenhagen, Denmark., Laius O; State Agency of Medicines, Tartu, Estonia., Martikainen JE; Pharmaceuticals Pricing Board, Ministry of Social Affairs and Health, Helsinki, Finland., Selke GW; AOK Research Institute (WIdO), Berlin, Germany., Kourafalos V; National Organization for the Provision of Healthcare Services (EOPYY), Athens, Greece., Magnússon E; Ministry of Welfare, Reykjavik, Iceland., Einarsdóttir R; The National University Hospital of Iceland, Reykjavik, Iceland., Adams R; St James's Hospital, Dublin, Ireland., Joppi R; Clinical Research and Drug Evaluation Unit, Local Health Authority of Verona, Verona, Italy., Allocati E; Mario Negri Institute for Pharmacological Research (IRCCS), Milan, Italy., Jakupi A; UBT - Higher Education Institute, Prishtina, Kosovo., Viksna A; Department of Medicines and Medical Devices, The National Health Service, Riga, Latvia., Greičiūtė-Kuprijanov I; Ministry of Health of the Republic of Lithuania, Vilnius, Lithuania., Vella Bonanno P; Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, United Kingdom., Suttorp V; Erasmus University Medical Center, Rotterdam, Netherlands., Melien Ø; Reviews and Health Technology Assessments, Norwegian Institute of Public Health, Oslo, Norway., Plisko R; HTA Consulting, Cracow, Poland., Mardare I; Public Health and Management Department, Faculty of Medicine, 'Carol Davila', University of Medicine and Pharmacy Bucharest, Bucharest, Romania., Meshkov D; V. A. Trapeznikov Institute of Control Sciences of Russian Academy of Sciences, Moscow, Russia., Novakovic T; ZEM Solutions, Belgrade, Serbia., Fürst J; Health Insurance Institute, Ljubljana, Slovenia., Zara C; Drug Area, Catalan Health Service, Barcelona, Spain., Marković-Peković V; Department of Social Pharmacy and Pharmacy Practice, Faculty of Medicine, University of Banja Luka, Banja Luka, Bosnia and Herzegovina., Grubiša N; Health Insurance Fund, Banja Luka, Bosnia and Herzegovina., Befrits G; Stockholm County Council, Stockholm, Sweden., Puckett R; NHS Greater Glasgow and Clyde, Queen Elizabeth University Hospital, Glasgow, United Kingdom., Vulto AG; Department of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.; Erasmus University Medical Center, Rotterdam, Netherlands.

Publikováno v: Frontiers in pharmacology [Front Pharmacol] 2021 Jan 08; Vol. 11, pp. 591134. Date of Electronic Publication: 2021 Jan 08 (Print Publication: 2020).